Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 195 clinical trials
Featured trial
EF-36/Keynote: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

This is a multicenter, single arm, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System concomitant with IV pembrolizumab (also known as MK-3475) in subjects previously untreated for their advance or metastatic intrathoracic, PD-L1 positive (TPS≥1% [tumor proportion score]) non-small cell lung …

  • 29 Nov, 2022
  • 1 location
Featured trial
GOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

GOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

  • 08 Nov, 2020
  • 1 location
Tislelizumab Plus Lenvatinib in Stage III-IV RCC (TILUR)

receive treatment with Tislelizumab in combination with Lenvatinib every 3 weeks unitl tumor progression or serious side effects

  • 04 Oct, 2022
  • 1 location
Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer

hypothesis considers that using Hyperthermic Intra-abdominal Chemotherapy,HIPEC, with gemcitabine after cytoreductive surgery ,will decrease tumor progression of pancreatic cancer by reducing the neoplastic

Accepts healthy volunteers
  • 31 Jan, 2022
  • 1 location
Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors

XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years. Patients will be closely monitored for safety and tolerability throughout

  • 05 Apr, 2022
  • 1 location
Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer (Optim-UCPVax)

survival compared with conventional systemic therapies, they fail to control cancer progression in a significant proportion of patients which can reach up to 50-60% in NSCLC. Recent literature highlights a

  • 24 May, 2022
  • 7 locations
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

their treatment course to obtain information about ongoing treatment and response, time to tumor progression and overall survival. These parameters will be used in correlational analysis with the

  • 27 Apr, 2022
  • 1 location
Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions

concept, i.e. a dynamic process between the tumour cells and the immune system including surveillance by the immune system or tumour progression. Thus, an imbalance in immunosuppressive microenvironment

  • 27 Jan, 2021
  • 5 locations
Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT

increase radio-resistance, failure of local control and tumor progression. Basing on data of experimental and clinical radiation oncology we consider hypoxia as a useful parameter for pre-therapeutic

  • 21 Jan, 2021
  • 2 locations
PREoperativ Study of Exercise Training (PRESET-RCT)

treatment failure, defined as the risk of not reaching surgery, in patients diagnosed with operable GE cancer. To explore the effect of preoperative exercise training on median time to tumor

tumor progression
esophageal adenocarcinoma
  • 12 Feb, 2022
  • 1 location